273 related articles for article (PubMed ID: 32702645)
1. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
Pasalic D; McGinnis GJ; Fuller CD; Grossberg AJ; Verma V; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Diefenhardt M; Das P; Subbiah V; Subbiah IM; Jagsi R; Garden AS; Fokas E; Rödel C; Thomas CR; Minsky BD; Ludmir EB
Eur J Cancer; 2020 Sep; 136():176-185. PubMed ID: 32702645
[TBL] [Abstract][Full Text] [Related]
2. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
[TBL] [Abstract][Full Text] [Related]
3. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises.
Hey SP; Gyawali B; D'Andrea E; Kanagaraj M; Franklin JM; Kesselheim AS
J Natl Cancer Inst; 2020 Apr; 112(4):335-342. PubMed ID: 31651981
[TBL] [Abstract][Full Text] [Related]
5. The value of surrogate endpoints for predicting real-world survival across five cancer types.
Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
[TBL] [Abstract][Full Text] [Related]
6. Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.
Johnson KR; Liauw W; Lassere MN
Ann Oncol; 2015 Mar; 26(3):485-96. PubMed ID: 25057168
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
8. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
9. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
11. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
12. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q; de Gramont A; Grothey A; Zalcberg J; Chibaudel B; Schmoll HJ; Seymour MT; Adams R; Saltz L; Goldberg RM; Punt CJ; Douillard JY; Hoff PM; Hecht JR; Hurwitz H; Díaz-Rubio E; Porschen R; Tebbutt NC; Fuchs C; Souglakos J; Falcone A; Tournigand C; Kabbinavar FF; Heinemann V; Van Cutsem E; Bokemeyer C; Buyse M; Sargent DJ
J Clin Oncol; 2015 Jan; 33(1):22-8. PubMed ID: 25385741
[TBL] [Abstract][Full Text] [Related]
13. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
14. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
15. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
Liang F; Zhang S; Wang Q; Li W
Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
17. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
18. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
